Two Deaths Reported to Regulators Potentially Linked to Weight-Loss Injections

Two deaths in Northern Ireland. At least 162 in the United States. More than 150 across the United Kingdom. As GLP-1 weight-loss injections become the fastest-growing drug class in pharmaceutical history, a growing body of adverse event reports is forcing regulators, clinicians, and patients to confront an uncomfortable question: just how safe are these drugs?

The reports do not prove the medications killed anyone. But they are arriving at a pace that has prompted new safety warnings, strengthened prescribing guidance, and a quiet reckoning within the medical establishment about whether the rush to treat obesity with injectable drugs has outpaced the evidence on their long-term risks.

Two Deaths in Northern Ireland Spotlight a Global Pattern

In March 2026, it emerged that two deaths in Northern Ireland had been reported to the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) over a potential link to GLP-1 weight-loss injections [1]. The deceased were a man and a woman — one in their 40s, the other in their 60s. One had been taking Mounjaro (tirzepatide), manufactured by Eli Lilly; the other was linked to an unspecified semaglutide medication, the active ingredient in Novo Nordisk's blockbuster brands Ozempic, Wegovy, and Rybelsus [1].

The two fatalities sit within a broader picture of more than 500 suspected adverse drug reaction reports submitted from Northern Ireland over the previous two years [1]. Of those, 242 were classified as serious and 267 as non-serious. Six cases involved acute pancreatitis — three suspected reactions to Mounjaro, one to Ozempic, and two to unspecified brands [1].

The overwhelming majority of these reports — 458 — were registered in 2025, compared to just 53 in 2024 [2], reflecting not just growing scrutiny but the explosive adoption of these medications. An estimated 1.6 million adults in England, Wales, and Scotland used GLP-1 drugs for weight loss between early 2024 and early 2025 [3].

Crucially, the MHRA stressed that a report of a suspected reaction "does not necessarily mean it has been caused by the medicine, only that the reporter had a suspicion it may have" [1]. The Coroners Service for Northern Ireland said that, from the limited information provided, it had been unable to identify any cases where GLP-1 medications were referred to as contributing toward a death [2].

The UK's Yellow Card System: 151 Deaths and Counting

The Northern Ireland reports are part of a much larger dataset. Across the entire United Kingdom, the MHRA's Yellow Card voluntary reporting system has received reports of at least 151 deaths associated with six different GLP-1 drugs [4]. Among individual products, Saxenda (liraglutide) was linked to the highest number of fatal reports at 37, followed by Mounjaro (tirzepatide) with 33 and semaglutide-based drugs with 30 deaths [4].

One case that drew particular public attention was that of Susan McGowan, a 58-year-old nurse from Scotland who died in September 2024 after taking just two low-dose injections of Mounjaro. Her death certificate listed pancreatitis, multiple organ failure, and septic shock [4].

By January 2025, the MHRA had recorded 82 deaths with a fatal outcome linked to GLP-1 drugs — a figure reported in the British Medical Journal and widely cited in media coverage [5]. By late 2025, that number had climbed past 170, including fatalities among adults in their 20s [6].

Source: GDELT Project

Data as of Mar 10, 2026CSV

The Pancreatitis Warning

The risk that most alarmed the MHRA was pancreatitis. On 29 January 2026, the regulator issued a formal Drug Safety Update strengthening warnings on acute pancreatitis — including necrotising and fatal cases — across all GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists [3].

Between 2007 and October 2025, the MHRA received 1,296 Yellow Card reports of pancreatitis associated with these drugs. Of those, 19 were fatal and 24 involved necrotising pancreatitis — a particularly severe form in which pancreatic tissue dies [3]. The update covered dulaglutide, exenatide, liraglutide, semaglutide, and tirzepatide.

The regulator's clinical guidance was unequivocal: if pancreatitis is suspected, the medication must be discontinued immediately and should not be restarted if the diagnosis is confirmed [3]. Healthcare professionals were also urged to ask patients about privately prescribed GLP-1 medications, which may not appear in NHS medical records [3].

Context matters here. Approximately 25.4 million packs of GLP-1 receptor agonists have been dispensed in the UK over the past five years [3]. Against that volume, 1,296 pancreatitis reports represent an extremely small incidence rate — but for the individuals affected, including the 19 who died, the consequences were catastrophic.

Across the Atlantic: 162 Deaths in the FDA's Database

The pattern extends well beyond the UK. In the United States, the Food and Drug Administration's Adverse Event Reporting System (FAERS) has logged at least 162 deaths linked to GLP-1 drugs since 2018 [7]. Of those, 94 were associated with semaglutide products (Ozempic and Wegovy), while 68 were linked to tirzepatide medications (Mounjaro or Zepbound) [7].

The total adverse event reports are staggering. The FDA has received at least 62,000 side-effect reports connected to these drugs, with roughly 10,000 classified as "serious" — meaning patients were hospitalized or experienced life-threatening complications [7]. Deaths linked to semaglutide and tirzepatide rose by 40% over a six-month period, with at least 117 new death reports added to the system in that timeframe [7].

As with the UK system, FAERS is a voluntary reporting mechanism. This means the true number of adverse events could be higher than recorded. Equally, it means that a report in the database does not establish causation between a drug and a death — only that a reporter suspected a connection [8].

The Compounding Crisis

A distinct but related danger has emerged from compounded versions of GLP-1 drugs — medications mixed by pharmacies rather than manufactured by the brand-name companies. Novo Nordisk CEO Lars Fruergaard Jorgensen warned in November 2024 that compounded semaglutide had been associated with at least 10 deaths and 100 hospitalizations [9].

By December 2024, the FDA's database listed more than 900 adverse events associated with compounded semaglutide and tirzepatide, of which 17 involved deaths [10]. The FDA identified several specific safety hazards: dosing errors arising from unit conversions between milligrams and other measurements, varying concentrations across compounded products, and the use of salt forms (such as semaglutide sodium and semaglutide acetate) that differ from the active ingredients in approved drugs [10].

Perhaps most alarming, the FDA found evidence of counterfeit compounded products with fraudulent labels — in some cases, the compounding pharmacies listed on the labels did not exist [10]. Nearly all compounded semaglutide is manufactured by foreign suppliers operating under their own quality standards, outside the FDA's premarket review process [10].

Clinical Evidence: A More Nuanced Picture

The adverse event reports tell one story. The clinical trial data tells another — and it is considerably more favorable to the drugs.

A major meta-analysis integrating evidence from 21 randomized controlled trials and 99,599 patients found that GLP-1 receptor agonists were associated with a 12% reduction in all-cause mortality compared to controls (HR 0.88, 95% CI 0.82–0.94, p=0.0001) [11]. The drugs also reduced myocardial infarction by 15%, heart failure hospitalizations by 11%, and a composite kidney outcome by 21% [11].

GLP-1 medications did increase gastrointestinal disorders by 63% and gallbladder disorders by 26%, but the meta-analysis found no statistically significant increase in pancreatitis or neoplasms between treatment and control groups [11].

This creates a paradox. The voluntary reporting systems are flagging deaths and severe pancreatitis cases, while the gold-standard clinical trial evidence suggests these drugs may actually reduce overall mortality — primarily through cardiovascular and metabolic benefits. The resolution likely lies in the difference between controlled trial populations and real-world patients, who may have additional comorbidities, use compounded or incorrectly dosed products, or take the drugs without adequate medical supervision.

The Scale of the Market

Understanding the safety signals requires appreciating the sheer scale of GLP-1 adoption. The global market for GLP-1 receptor agonists was valued at approximately $51.9 billion in 2024 and is projected to reach $137.4 billion by 2030, growing at a compound annual growth rate of 17.6% [12]. Semaglutide-based products (primarily Wegovy) accounted for 60.7% of the weight-loss segment in 2024 [12].

Yet market penetration remains remarkably low. Only about 7% of diabetes patients and 2% of the obese population globally are currently using GLP-1 medications [12]. With the FDA's December 2025 approval of the first oral GLP-1 pill for obesity, Novo Nordisk's oral semaglutide, and Eli Lilly's pipeline of next-generation treatments, the number of users is expected to grow dramatically [13].

This growth trajectory makes robust post-market safety surveillance not merely important but essential. If adverse events occur at even a tiny percentage of use, the absolute numbers will climb as millions more patients gain access.

The Obesity Paradox

Any assessment of GLP-1 drug safety must be weighed against the condition they treat. Obesity is linked to approximately 300,000 deaths per year in the United States and 30,000 deaths annually in the United Kingdom [14]. Globally, the World Health Organization estimates that at least 2.8 million people die each year from being overweight or obese [15].

By this calculus, even imperfect weight-loss medications that carry rare but serious risks may represent a net benefit to public health — provided patients are properly screened, supervised, and informed. The challenge lies in ensuring that the explosive demand for these drugs, driven in part by social media and celebrity culture, does not outstrip the healthcare system's capacity to prescribe them safely.

What Needs to Change

Several concrete steps are already underway. The MHRA's January 2026 Drug Safety Update strengthened pancreatitis warnings and instructed healthcare professionals to discontinue treatment at the first sign of the condition [3]. The FDA has issued multiple alerts about compounded semaglutide and is pursuing enforcement against fraudulent products [10].

Dr. Alison Cave, the MHRA's Chief Safety Officer, has stated that "patient safety is our top priority and no medicine would be approved unless it met our expected standards" [5]. Dr. Martin Michaelis of the University of Kent has offered a more measured assessment: weight-loss drugs "are associated with side effects that can be severe or even life-threatening in a small minority" [5].

The gap between those two statements — between assurance and acknowledgment — defines the current moment. GLP-1 drugs are not going away. They are expanding into oral formulations, new indications (including heart failure, kidney disease, and addiction), and broader patient populations. The question is not whether they will be used at scale, but whether the systems designed to monitor their safety can keep pace with a pharmaceutical revolution that is moving faster than any in recent memory.

For the families of the two people who died in Northern Ireland — and the hundreds of others across the UK and the US whose deaths have been flagged to regulators — the statistics are immaterial. What matters is whether anyone was warned, whether anyone was watching, and whether the system will learn from what it finds.